Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells

Ai Kotani; Atsushi Takahashi; Hikari Koga; Rinpei Morita; Hidenao Fukuyama; Tatsuo Ichinohe; Takayuki Ishikawa; Toshiyuki Hori; Takashi Uchiyama

doi:10.1034/j.1600-0609.2002.02789.x

Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40⁺ CD4⁺ T cells

Ai Kotani, Atsushi Takahashi, Hikari Koga, Rinpei Morita, Hidenao Fukuyama, Tatsuo Ichinohe, Takayuki Ishikawa, Toshiyuki Hori, Takashi Uchiyama

Department of Microbiology and Immunology

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

A patient who developed myasthenia gravis (MG) 25 months after allogeneic bone marrow transplant was immunologically analyzed. OX40⁺ CD4⁺ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF). Monitoring of OX40⁺ CD4⁺ T cells supported the tapering of PSL and MMF as a marker of cGVHD activity. This case suggested the utility of MMF and monitoring of OX40⁺ CD4⁺ T cells in the management of cGVHD-associated autoimmune diseases.

Original language	English
Pages (from-to)	318-320
Number of pages	3
Journal	European Journal of Haematology
Volume	69
Issue number	5-6
DOIs	https://doi.org/10.1034/j.1600-0609.2002.02789.x
Publication status	Published - 2002 Nov 1

Keywords

Chronic graft-vs.-host disease
Myasthenia gravis
Mycophenolate mofetil
OX40

ASJC Scopus subject areas

Hematology

Access to Document

10.1034/j.1600-0609.2002.02789.x

Cite this

Kotani, A., Takahashi, A., Koga, H., Morita, R., Fukuyama, H., Ichinohe, T., Ishikawa, T., Hori, T., & Uchiyama, T. (2002). Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40⁺ CD4⁺ T cells. European Journal of Haematology, 69(5-6), 318-320. https://doi.org/10.1034/j.1600-0609.2002.02789.x

Kotani, A, Takahashi, A, Koga, H, Morita, R, Fukuyama, H, Ichinohe, T, Ishikawa, T, Hori, T & Uchiyama, T 2002, 'Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40⁺ CD4⁺ T cells', European Journal of Haematology, vol. 69, no. 5-6, pp. 318-320. https://doi.org/10.1034/j.1600-0609.2002.02789.x

@article{dc9b8b1fc60a45c483959b464599daba,

title = "Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells",

abstract = "A patient who developed myasthenia gravis (MG) 25 months after allogeneic bone marrow transplant was immunologically analyzed. OX40+ CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF). Monitoring of OX40+ CD4+ T cells supported the tapering of PSL and MMF as a marker of cGVHD activity. This case suggested the utility of MMF and monitoring of OX40+ CD4+ T cells in the management of cGVHD-associated autoimmune diseases.",

keywords = "Chronic graft-vs.-host disease, Myasthenia gravis, Mycophenolate mofetil, OX40",

author = "Ai Kotani and Atsushi Takahashi and Hikari Koga and Rinpei Morita and Hidenao Fukuyama and Tatsuo Ichinohe and Takayuki Ishikawa and Toshiyuki Hori and Takashi Uchiyama",

year = "2002",

month = nov,

day = "1",

doi = "10.1034/j.1600-0609.2002.02789.x",

language = "English",

volume = "69",

pages = "318--320",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "5-6",

}

TY - JOUR

T1 - Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells

AU - Kotani, Ai

AU - Takahashi, Atsushi

AU - Koga, Hikari

AU - Morita, Rinpei

AU - Fukuyama, Hidenao

AU - Ichinohe, Tatsuo

AU - Ishikawa, Takayuki

AU - Hori, Toshiyuki

AU - Uchiyama, Takashi

PY - 2002/11/1

Y1 - 2002/11/1

N2 - A patient who developed myasthenia gravis (MG) 25 months after allogeneic bone marrow transplant was immunologically analyzed. OX40+ CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF). Monitoring of OX40+ CD4+ T cells supported the tapering of PSL and MMF as a marker of cGVHD activity. This case suggested the utility of MMF and monitoring of OX40+ CD4+ T cells in the management of cGVHD-associated autoimmune diseases.

AB - A patient who developed myasthenia gravis (MG) 25 months after allogeneic bone marrow transplant was immunologically analyzed. OX40+ CD4+ T cells in the peripheral blood prominently increased one month before the onset of MG. CD4/CD8 ratios, usually abnormally inverted in patients with chronic graft-vs.-host disease (cGVHD), showed pseudonormalization during the course of MG. We succeeded in uneventful rapid tapering of prednisolone (PSL) using mycophenolate mofetil (MMF). Monitoring of OX40+ CD4+ T cells supported the tapering of PSL and MMF as a marker of cGVHD activity. This case suggested the utility of MMF and monitoring of OX40+ CD4+ T cells in the management of cGVHD-associated autoimmune diseases.

KW - Chronic graft-vs.-host disease

KW - Myasthenia gravis

KW - Mycophenolate mofetil

KW - OX40

UR - http://www.scopus.com/inward/record.url?scp=0036867536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036867536&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0609.2002.02789.x

DO - 10.1034/j.1600-0609.2002.02789.x

M3 - Article

C2 - 12460238

AN - SCOPUS:0036867536

VL - 69

SP - 318

EP - 320

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 5-6

ER -